Dehydroabietic acid (Synonyms: デヒドロアビエチン酸)

Name: Dehydroabietic acid
Brand: MedChemExpress
SKU: HY-N6869
Rating: 4.5 (1 reviews)

製品番号: HY-N6869 純度: 98.52%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Dehydroabietic acid is a diterpene resin acid that can be isolated from Pinus and Picea. Dehydroabietic acid has anti-bacterial, anti-fungal, anti-inflammatory, and anticancer activities. Dehydroabietic acid is a dual PPAR-α/γ agonist and PPAR-γ partial agonist, which can attenuate insulin resistance (IR) and hepatic steatosis induced by HFD-consumption in mice.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

Dehydroabietic acid 構造式

CAS 番号 : 1740-19-8

容量	価格（税別）	在庫状況	数量
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 77	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 77	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$70	在庫あり	Estimated Time of Arrival: December 31
10 mg	$120	在庫あり	Estimated Time of Arrival: December 31
20 mg	$200	在庫あり	Estimated Time of Arrival: December 31
50 mg		お問い合わせ
100 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 1 publication(s) in Google Scholar

Other Forms of Dehydroabietic acid:

(+)-Dehydroabietic acid お問い合わせ
Dehydroabietic acid (Standard) お問い合わせ

顧客検証

•S Afr J Bot. 2025 Sep.

Antibiotic アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

PPAR アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

PPARα PPARβ/δ PPARγ PPAR PPARδ

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
5637	IC₅₀	27.59 3 Compound: 1, DHAA	Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
5637	IC₅₀	27.59 3 Compound: 1, DHAA	Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
5637	IC₅₀	27.59 3 Compound: 1, DHAA	Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human 5637 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
A549	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human A549 cells by SRB assay Cytotoxicity in human A549 cells by SRB assay	[PMID: 26812172]
A549	IC₅₀	>50 3 Compound: 1; DHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
A549	IC₅₀	55.65 3 Compound: DHAA	Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
A549	IC₅₀	74.33 3 Compound: 5	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
A549	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
A549	IC₅₀	55.65 3 Compound: DHAA	Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
A549	IC₅₀	74.33 3 Compound: 5	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
A549	IC₅₀	79.46 3 Compound: 4, DHA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23988357]
A549	IC₅₀	55.65 3 Compound: DHAA	Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human A549 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
A549	IC₅₀	79.46 3 Compound: DHA	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 24095745]
A549	IC₅₀	74.33 3 Compound: 5	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
A549	IC₅₀	79.46 3 Compound: DHA	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 24095745]
A549	IC₅₀	79.46 3 Compound: 4, DHA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23988357]
A549	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human A549 cells by SRB assay Cytotoxicity in human A549 cells by SRB assay	[PMID: 26812172]
A549	IC₅₀	79.46 3 Compound: DHA	Cytotoxicity against human A549 cells after 3 days by MTT assay Cytotoxicity against human A549 cells after 3 days by MTT assay	[PMID: 24095745]
A549	IC₅₀	>10 3 Compound: 19	Cytotoxicity in human A549 cells by SRB assay Cytotoxicity in human A549 cells by SRB assay	[PMID: 26812172]
A549	IC₅₀	79.46 3 Compound: 4, DHA	Cytotoxicity against human A549 cells after 48 hrs by MTT assay Cytotoxicity against human A549 cells after 48 hrs by MTT assay	[PMID: 23988357]
A549	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
BEL-7404 tumor cell line	IC₅₀	28.72 3 Compound: DHAA	Cytotoxic activity against human Bel7404 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human Bel7404 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
BEL-7404 tumor cell line	IC₅₀	28.72 3 Compound: DHAA	Cytotoxic activity against human Bel7404 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human Bel7404 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
BEL-7404 tumor cell line	IC₅₀	34.7 3 Compound: DHA	Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay	[PMID: 24565905]
BEL-7404 tumor cell line	IC₅₀	34.7 3 Compound: DHA	Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay Cytotoxicity against human Bel7404 cells after 48 hrs by MTT assay	[PMID: 24565905]
EJ	IC₅₀	25.12 3 Compound: 1, DHAA	Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
EJ	IC₅₀	25.12 3 Compound: 1, DHAA	Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
EJ	IC₅₀	25.12 3 Compound: 1, DHAA	Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human EJ cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HCT-116	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human HCT116 cells by SRB assay Cytotoxicity in human HCT116 cells by SRB assay	[PMID: 26812172]
HCT-116	IC₅₀	30.25 3 Compound: DHAA	Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
HCT-116	IC₅₀	30.25 3 Compound: DHAA	Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
HCT-116	IC₅₀	35.24 3 Compound: DHA	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24565905]
HCT-116	IC₅₀	30.25 3 Compound: DHAA	Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human HCT116 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
HCT-116	IC₅₀	35.24 3 Compound: DHA	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24565905]
HCT-116	IC₅₀	>10 3 Compound: 19	Cytotoxicity in human HCT116 cells by SRB assay Cytotoxicity in human HCT116 cells by SRB assay	[PMID: 26812172]
HCT-116	IC₅₀	35.24 3 Compound: DHA	Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay Cytotoxicity against human HCT116 cells after 48 hrs by MTT assay	[PMID: 24565905]
HCT-116	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human HCT116 cells by SRB assay Cytotoxicity in human HCT116 cells by SRB assay	[PMID: 26812172]
HEK293	IC₅₀	> 100 6 Compound: 31	Inhibition of TNF-alpha-induced NF-kappaB activity in human pNF-kappaB-luc-293 cells Inhibition of TNF-alpha-induced NF-kappaB activity in human pNF-kappaB-luc-293 cells	[PMID: 20022253]
HEK293	IC₅₀	>100 6 Compound: 31	Inhibition of TNF-alpha-induced NF-kappaB activity in human pNF-kappaB-luc-293 cells Inhibition of TNF-alpha-induced NF-kappaB activity in human pNF-kappaB-luc-293 cells	[PMID: 20022253]
HeLa	IC₅₀	101 6 Compound: 4, dehydroabietic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19892441]
HeLa	IC₅₀	28.43 3 Compound: 1, DHAA	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HeLa	IC₅₀	30.35 3 Compound: 1; DHA	Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
HeLa	IC₅₀	101 6 Compound: 4, dehydroabietic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19892441]
HeLa	IC₅₀	101 6 Compound: 4, dehydroabietic acid	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19892441]
HeLa	IC₅₀	29.35 3 Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462253]
HeLa	IC₅₀	29.35 3 Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24565905]
HeLa	IC₅₀	29.35 3 Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24565905]
HeLa	IC₅₀	28.43 3 Compound: 1, DHAA	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HepG2	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
HeLa	IC₅₀	29.35 3 Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462253]
HeLa	IC₅₀	29.35 3 Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 24565905]
HepG2	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28756264]
HeLa	IC₅₀	28.43 3 Compound: 1, DHAA	Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HeLa	IC₅₀	29.35 3 Compound: DHA	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 25462253]
HepG2	IC₅₀	80.36 3 Compound: 1; DHA	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
HepG2	IC₅₀	76.76 3 Compound: DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24565905]
HeLa	IC₅₀	30.35 3 Compound: 1; DHA	Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
HepG2	IC₅₀	>50 3 Compound: DHAA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28756264]
HepG2	IC₅₀	76.76 3 Compound: DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24565905]
HepG2	IC₅₀	85 3 Compound: DHA	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 24095745]
HepG2	IC₅₀	85 3 Compound: 4, DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23988357]
HepG2	IC₅₀	80.36 3 Compound: 1; DHA	Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
HepG2	IC₅₀	>50 3 Compound: 1; DHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
Jurkat	IC₅₀	25.51 3 Compound: 1, DHAA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
HepG2	IC₅₀	85 3 Compound: DHA	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 24095745]
HepG2	IC₅₀	85 3 Compound: 4, DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23988357]
HepG2	IC₅₀	85 3 Compound: DHA	Cytotoxicity against human HepG2 cells after 3 days by MTT assay Cytotoxicity against human HepG2 cells after 3 days by MTT assay	[PMID: 24095745]
Jurkat	IC₅₀	28 6 Compound: 4, dehydroabietic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 19892441]
HepG2	IC₅₀	76.76 3 Compound: DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 24565905]
L02	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
HepG2	IC₅₀	85 3 Compound: 4, DHA	Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 23988357]
HepG2	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
HepG2	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay	[PMID: 28756264]
L02	IC₅₀	> 50 3 Compound: DHAA	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 28756264]
Jurkat	IC₅₀	28 6 Compound: 4, dehydroabietic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 19892441]
L6	IC₅₀	101.3 3 Compound: 1	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis	10.1039/C5MD00498E
Jurkat	IC₅₀	25.51 3 Compound: 1, DHAA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
Jurkat	IC₅₀	25.51 3 Compound: 1, DHAA	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
L6	IC₅₀	151 3 Compound: 1	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	10.1039/C5MD00498E
L02	IC₅₀	>50 3 Compound: 1; DHA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
Jurkat	IC₅₀	28 6 Compound: 4, dehydroabietic acid	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 19892441]
L02	IC₅₀	> 100 3 Compound: 1; DHA	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38389893]
MCF7	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28756264]
L02	IC₅₀	>50 3 Compound: DHAA	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 28756264]
MGC-803	IC₅₀	> 100 3 Compound: DHA	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 25462253]
L02	IC₅₀	>100 3 Compound: 1; DHA	Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human LO2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 38389893]
L02	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human L02 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
L6	IC₅₀	101.3 3 Compound: 1	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis	10.1039/C5MD00498E
MGC-803	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
L02	IC₅₀	> 50 3 Compound: DHAA	Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay Cytotoxicity against human HL-7702 cells after 48 hrs by MTT assay	[PMID: 28756264]
NCI-H460	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 28756264]
L6	IC₅₀	151 3 Compound: 1	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	10.1039/C5MD00498E
L6	IC₅₀	101.3 3 Compound: 1	Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis Antiparasitic activity against amastigote stage of Trypanosoma cruzi Tulahuen C2C4 expressing LacZ gene infected in rat L6 cells after 96 hrs by photometric analysis	10.1039/C5MD00498E
L6	IC₅₀	151 3 Compound: 1	Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay Cytotoxicity against rat L6 cells after 72 hrs by Alamar blue assay	10.1039/C5MD00498E
LoVo	IC₅₀	>25 6 Compound: 31	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 20022253]
NCI-H460	IC₅₀	75.05 3 Compound: DHAA	Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
MCF7	IC₅₀	>50 3 Compound: DHAA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28756264]
NCI-H460	IC₅₀	80.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 24565905]
LoVo	IC₅₀	> 25 6 Compound: 31	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 20022253]
MCF7	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 28756264]
MGC-803	IC₅₀	>100 3 Compound: 1; DHA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
NCI-H460	IC₅₀	84.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay	[PMID: 24095745]
NCI-H460	IC₅₀	84.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 25462253]
MGC-803	IC₅₀	>50 3 Compound: 1; DHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
MGC-803	IC₅₀	> 100 3 Compound: 1; DHA	Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human MGC-803 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
MGC-803	IC₅₀	>100 3 Compound: DHA	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 25462253]
NCI-H460	IC₅₀	84.53 3 Compound: 4, DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 23988357]
MGC-803	IC₅₀	> 100 3 Compound: DHA	Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay	[PMID: 25462253]
PC-3	IC₅₀	28.1 3 Compound: 1, DHAA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
NCI-H460	IC₅₀	>50 3 Compound: DHAA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 28756264]
MGC-803	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human MGC-803 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
PC-3	IC₅₀	51.31 3 Compound: 5	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
NCI-H460	IC₅₀	75.05 3 Compound: DHAA	Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
NCI-H460	IC₅₀	75.05 3 Compound: DHAA	Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human NCI-H460 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
NCI-H460	IC₅₀	84.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay	[PMID: 24095745]
SK-MEL-2	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human SK-MEL-2 cells by SRB assay Cytotoxicity in human SK-MEL-2 cells by SRB assay	[PMID: 26812172]
SK-OV-3	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human SKOV3 cells by SRB assay Cytotoxicity in human SKOV3 cells by SRB assay	[PMID: 26812172]
NCI-H460	IC₅₀	80.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 24565905]
NCI-H460	IC₅₀	80.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 24565905]
SK-OV-3	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 28756264]
NCI-H460	IC₅₀	84.53 3 Compound: 4, DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 23988357]
NCI-H460	IC₅₀	84.53 3 Compound: 4, DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 23988357]
SK-OV-3	IC₅₀	65.06 3 Compound: DHAA	Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
NCI-H460	IC₅₀	84.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 25462253]
NCI-H460	IC₅₀	84.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay Cytotoxicity against human NCI-H460 cells after 3 days by MTT assay	[PMID: 24095745]
PC-3	IC₅₀	51.31 3 Compound: 5	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	65.96 3 Compound: 5	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
NCI-H460	IC₅₀	84.53 3 Compound: DHA	Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay Cytotoxicity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 25462253]
PC-3	IC₅₀	28.1 3 Compound: 1, DHAA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
SK-OV-3	IC₅₀	75 3 Compound: DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24565905]
NCI-H460	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay Antiproliferative activity against human NCI-H460 cells after 48 hrs by MTT assay	[PMID: 28756264]
QGY-7703	IC₅₀	>25 6 Compound: 31	Antiproliferative activity against human QGY7703 cells Antiproliferative activity against human QGY7703 cells	[PMID: 20022253]
SK-OV-3	IC₅₀	84 3 Compound: DHA	Cytotoxicity against human SKOV3 cells after 3 days by MTT assay Cytotoxicity against human SKOV3 cells after 3 days by MTT assay	[PMID: 24095745]
PC-3	IC₅₀	28.1 3 Compound: 1, DHAA	Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human PC3 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 23707051]
PC-3	IC₅₀	51.31 3 Compound: 5	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
RAW264.7	IC₅₀	42.7 6 Compound: 31	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release	[PMID: 20022253]
SK-OV-3	IC₅₀	84 3 Compound: 4, DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 23988357]
QGY-7703	IC₅₀	> 25 6 Compound: 31	Antiproliferative activity against human QGY7703 cells Antiproliferative activity against human QGY7703 cells	[PMID: 20022253]
T-24	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
SK-MEL-2	IC₅₀	>10 3 Compound: 19	Cytotoxicity in human SK-MEL-2 cells by SRB assay Cytotoxicity in human SK-MEL-2 cells by SRB assay	[PMID: 26812172]
Vero	IC₅₀	20 6 Compound: 5	Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells	10.1016/S0960-894X(01)80236-5
SK-OV-3	IC₅₀	>50 3 Compound: DHAA	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 28756264]
RAW264.7	IC₅₀	42.7 6 Compound: 31	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO release	[PMID: 20022253]
SK-OV-3	IC₅₀	65.06 3 Compound: DHAA	Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
Vero	IC₅₀	91 6 Compound: 4, dehydroabietic acid	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 19892441]
SK-OV-3	IC₅₀	65.96 3 Compound: 5	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	84 3 Compound: DHA	Cytotoxicity against human SKOV3 cells after 3 days by MTT assay Cytotoxicity against human SKOV3 cells after 3 days by MTT assay	[PMID: 24095745]
SK-OV-3	IC₅₀	75 3 Compound: DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24565905]
SK-OV-3	IC₅₀	84 3 Compound: 4, DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 23988357]
SK-OV-3	IC₅₀	>10 3 Compound: 19	Cytotoxicity in human SKOV3 cells by SRB assay Cytotoxicity in human SKOV3 cells by SRB assay	[PMID: 26812172]
T-24	IC₅₀	>100 3 Compound: 1; DHA	Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
T-24	IC₅₀	>50 3 Compound: 1; DHA	Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
Vero	IC₅₀	20 6 Compound: 5	Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells	10.1016/S0960-894X(01)80236-5
SK-MEL-2	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human SK-MEL-2 cells by SRB assay Cytotoxicity in human SK-MEL-2 cells by SRB assay	[PMID: 26812172]
Vero	IC₅₀	91 6 Compound: 4, dehydroabietic acid	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 19892441]
SK-OV-3	IC₅₀	65.06 3 Compound: DHAA	Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay Cytotoxic activity against human SKOV3 cells assessed as inhibition of cell growth after 48 hrs by MTT assay	[PMID: 26706349]
SK-OV-3	IC₅₀	65.96 3 Compound: 5	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	75 3 Compound: DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 24565905]
SK-OV-3	IC₅₀	84 3 Compound: 4, DHA	Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay Cytotoxicity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 23988357]
SK-OV-3	IC₅₀	84 3 Compound: DHA	Cytotoxicity against human SKOV3 cells after 3 days by MTT assay Cytotoxicity against human SKOV3 cells after 3 days by MTT assay	[PMID: 24095745]
SK-OV-3	IC₅₀	> 10 3 Compound: 19	Cytotoxicity in human SKOV3 cells by SRB assay Cytotoxicity in human SKOV3 cells by SRB assay	[PMID: 26812172]
SK-OV-3	IC₅₀	> 50 3 Compound: DHAA	Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay Antiproliferative activity against human SKOV3 cells after 48 hrs by MTT assay	[PMID: 28756264]
T-24	IC₅₀	> 100 3 Compound: 1; DHA	Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Anticancer activity against human T-24 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 38389893]
T-24	IC₅₀	> 50 3 Compound: 1; DHA	Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay Antiproliferative activity against human T24 cells assessed as reduction in cell viability measured for 24 hrs by MTT assay	[PMID: 37122546]
Vero	IC₅₀	20 6 Compound: 5	Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells	10.1016/S0960-894X(01)80236-5
Vero	IC₅₀	91 6 Compound: 4, dehydroabietic acid	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 19892441]

体外実験

Dehydroabietic acid (0-100 μM, 30 min) decreases NO production in RAW264.7 cells^[1].
Dehydroabietic acid (0-100 μM, 6 h) reduces the mRNA expression levels of inflammatory mediators including inducible nitric oxide (iNOS) and TNF-α in RAW264.7 cells^[1].
Dehydroabietic acid (0-100 μM, 24 h) reduces the MyD88-induced NF-κB and AP-1 transcriptional activities in HEK293T cells^[1].
Dehydroabietic acid (100 μM, 24 h) inactivates both Src and Syk kinases in Src- or Syk-overexpressing HEK293T cells^[1].
Dehydroabietic acid (2.5-15 μM, 4 days) promotes 3T3-L1 adipocyte differentiation in a dose-dependent manner^[2].
Dehydroabietic acid (10 μM, 0-6 days) increases mRNA expression of PPAR-γ target genes (Glut-4 and Cyp4a10) in 3T3-L1 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	AW264.7 cells
Concentration:	100 μM
Incubation Time:	5-60 min, 120-240 min
Result:	Blocked the phosphorylation of IκBα at 5 and 15 min. Reduced c-Jun N-terminal kinase (JNK) phosphorylation. Reduced phosphorylated levels of mitogen-activated protein kinase kinase 4 (MKK4) and MKK7 at 60 mim. Decreased the phosphorylation of MKK4 and MKK7 and their downstream protein JNK at 120 and 240 min.

体内実験

Dehydroabietic acid (10-20 mg/kg, i.g., daily, 9 weeks) alleviates HFD-induced hepatic steatosis and inflammation in HFD mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HFD mice^[2]
Dosage:	10-20 mg/kg
Administration:	i.g., daily, 9 weeks
Result:	Decreased the levels of liver injury markers, ALT and AST. Decreased blood TG, TC and LDL-c levels and increased the HDL-c levels. Activated PPAR-α and its target gene which were reduced by HFD, including acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain and CPT1α. Decreased mRNA expression of inflammatory factors commonly involved in liver diseases and injury (IL-1β, IL-6, TNF-α, COX-1 and COX-2). Upregulated mRNA expression of PPAR-γ, Glut-4, Adipor, FSP27, ACOX-1, FABP4, Adiponectin.

分子量

300.44

分子式

C₂₀H₂₈O₂

CAS 番号

1740-19-8

Appearance

Solid

Color

White to light yellow

SMILES

O=C([C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C=C3)O

Structure Classification

Initial Source

Microorganisms

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (332.85 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3285 mL	16.6423 mL	33.2845 mL
5 mM	0.6657 mL	3.3285 mL	6.6569 mL
10 mM	0.3328 mL	1.6642 mL	3.3285 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 98.52%

Select Batch:

データシート (278 KB) SDS (624 KB)

COA (248 KB) HNMR (248 KB) LCMS (99 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Kim E, et al. Dehydroabietic Acid Suppresses Inflammatory Response Via Suppression of Src-, Syk-, and TAK1-Mediated Pathways. Int J Mol Sci. 2019 Mar 29;20(7):1593. [Content Brief]

[2]. Xie Z, et al. Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. Biomed Pharmacother. 2020 Jul;127:110155. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.3285 mL	16.6423 mL	33.2845 mL	83.2113 mL
	5 mM	0.6657 mL	3.3285 mL	6.6569 mL	16.6423 mL
	10 mM	0.3328 mL	1.6642 mL	3.3285 mL	8.3211 mL
	15 mM	0.2219 mL	1.1095 mL	2.2190 mL	5.5474 mL
	20 mM	0.1664 mL	0.8321 mL	1.6642 mL	4.1606 mL
	25 mM	0.1331 mL	0.6657 mL	1.3314 mL	3.3285 mL
	30 mM	0.1109 mL	0.5547 mL	1.1095 mL	2.7737 mL
	40 mM	0.0832 mL	0.4161 mL	0.8321 mL	2.0803 mL
	50 mM	0.0666 mL	0.3328 mL	0.6657 mL	1.6642 mL
	60 mM	0.0555 mL	0.2774 mL	0.5547 mL	1.3869 mL
	80 mM	0.0416 mL	0.2080 mL	0.4161 mL	1.0401 mL
	100 mM	0.0333 mL	0.1664 mL	0.3328 mL	0.8321 mL

Dehydroabietic acid Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Dehydroabietic acid (Synonyms: デヒドロアビエチン酸)

カスタマーレビュー

Other Forms of Dehydroabietic acid:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

PPAR アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Dehydroabietic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Dehydroabietic acid (Synonyms: デヒドロアビエチン酸)

カスタマーレビュー

Other Forms of Dehydroabietic acid:

Dehydroabietic acid 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Antibiotic アイソフォーム固有の製品をすべて表示:

PPAR アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Dehydroabietic acid 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Dehydroabietic acid Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report